Pre-transplant ¹⁸FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation

References

• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Anderson J R, Vose J M, Bierman P J, Weisenberger D D, Sanger W G, Pierson J, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J O, Spitzer G, Chauvin F, Jagannath S, Cahn J Y, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Kewalramani T, Nimer S D, Gonzalez M, Zelenetz A D, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652
   PubMed Web of Science ®Google Scholar
• Comparison of HD Chemotherapy Followed by Auto-Transplant and R-CHOP in High Risk Patients With DLBCL. http://clinicaltrials.gov/show/NCT00355199
   Google Scholar
• Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21: 1802.11
   Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Moog F, Bangerter M, Diederichs C G, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795–800
   PubMed Web of Science ®Google Scholar
• Moog F, Bangerter M, Diederichs C G, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475–481
   PubMed Web of Science ®Google Scholar
• Schaefer N G, Strobel K, Taverna C, Hany T F. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007; 34: 60–67
   PubMed Web of Science ®Google Scholar
• Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, Coya J, Rodriguez-Vigil B, Madero R, et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 2006; 135: 293–302
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 2001; 19: 414–419
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613–618
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773–1782
   PubMed Web of Science ®Google Scholar
• Romer W, Hanauske A R, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464–4471
   PubMed Web of Science ®Google Scholar
• Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
   PubMed Web of Science ®Google Scholar
• Freudenberg L S, Antoch G, Schutt P, Beyer T, Jentzen W, Muller S P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325–329
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007; 7: 291–295
   PubMedGoogle Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429–433
   PubMed Web of Science ®Google Scholar
• Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau J L, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006; 85: 759–767
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475–481
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Pedersen L M, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Berthelsen A K, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 2007; 78: 206–212
   PubMed Web of Science ®Google Scholar
• Schot B W, Zijlstra J M, Sluiter W J, van Imhoff G W, Pruim J, Vaalburg W, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109: 486–491
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Cox D R. Regression models and life tables. J R Stat Soc 1972; 34(Series B)187–220
   Google Scholar
• Schot B W, Pruim J, van Imhoff G W, Sluiter W J, Vaalburg W, Vellenga E. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91: 490–495
   PubMed Web of Science ®Google Scholar
• Filmont J E, Czernin J, Yap C, Silverman D H, Quon A, Phelps M E, et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124: 608–613
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Elstrom R, Chong E A, Downs L H, Berkowitz A, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211–216
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53–59
   PubMed Web of Science ®Google Scholar
• Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix H T, Karanikas G, et al. Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260–267
   PubMed Web of Science ®Google Scholar
• Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481–2489
   PubMed Web of Science ®Google Scholar
• Filmont J E, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361–1369
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323
   PubMed Web of Science ®Google Scholar